Elucidating the potential associations between USP30-AS1 expression and clinical outcomes would facilitate the emergence of pioneering diagnostic and therapeutic approaches that have the potential to enhance the clinical outcomes and survival rates of patients with ovarian cancer. This evidence concerns the gene USP30 and ovarian carcinoma.